The NDA is based on results from REDEFINE 1, a 68-week, phase 3, randomised, double-blind, placebo-and active-controlled trial that evaluated the efficacy and safety of once-weekly, CagriSema compared to semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo, all as an adjunct to lifestyle intervention in 3,417 adults with obesity (BMI 30 kg/m2) or overweight (BMI 27 kg/m2) with one or more obesity-related complications and without diabetes, and REDEFINE 2, a double-blind, randomised, placebo-controlled, 68-week, phase 3 trial that evaluated the efficacy and safety of once-weekly CagriSema versus placebo, as an adjunct to lifestyle intervention in 1,206 adults with type 2 diabetes and either obesity (BMI 30 kg/m2) or overweight (BMI 27 kg/m2)
Nonetheless, these adverse events were transient and the blood parameters promptly returned to their normal values upon cessation of consumption
10.1136/gutjnl-2022-327745 64 MalfertheinerP.SchulzC.HuntR
And they go, oh, nutrition, oh, exercise, oh, I gotta drink more water
This peptide has been studied for its potential role in supporting biological rhythm regulation and sleep wellness
Formulation Considerations Research-grade GHK-Cu is typically supplied as a lyophilized (freeze-dried) peptide to improve stability during storage and transportation
